Sagar Dave

Working in Marketing Dept in Multibaggar 😉 Pharma Co. Value Investor & Financial Enthusiast, Eternal Optimistic.

A Son on Mission to fullfill his Dad's dream.

[Sagar Dave @SagarDave2612]

Simplified #valueinvesting

[Vivek @Vivek_Investor]

Warren Buffett in a Nutshell @Gautam__Baid @dmuthuk @RonBeaubien

[Reads with Ravi @readswithravi]

There’s an old Chinese proverb that I love:

“He who blames others has a long way to go on his journey. He who blames himself is halfway there. He who blames no one has arrived.”

[Investment Wisdom @InvestingCanons]

"Dream big and be prepared mentally and financially to act fast when opportunities present themselves. Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold."

— Warren Buffett

[ET NOW @ETNOWlive]

The 2026 World Humanoid Robot Games are officially underway in Beijing! Over 2,000 droids from 16 countries are competing in everything from soccer and boxing to a fully autonomous 100m sprint that just beat Usain Bolt's record. 🏃‍♂️💨

From synchronized marching to epic track stumbles and Ronaldo "Siuuu" celebrations, the future is officially here. 🦾⚡

#AI #robots #tech #racing

[Money Wisdom @MoneyWisdom_]

A high income is the first half of the equation.

The second is the ability to choose how, where, and with whom you spend your life.

Freedom's what makes earning money worth it.

[Epic Man Thinker @NMasculine7]

Messages To Never Send As A Man

-Thread-

[Reads with Ravi @readswithravi]

What begins as intention becomes character through repetition.

[Sagar Dave @SagarDave2612]

@Chart_Wallah108 Swan corp

[Peter Mallouk @PeterMallouk]

"I like to deal with people where I feel a one-page contract will do the job. If I have to have 50 pages in there to protect me against the guy I'm dealing with, I'll always wonder whether I needed 51." – Warren Buffett

[Investment Wisdom @InvestingCanons]

"Being prepared, on a few occasions in a lifetime, to act promptly in scale, in doing some simple and logical thing, will often dramatically improve the financial results of that lifetime."

— Charlie Munger

[Sunil Gurjar, CFTe @sunilgurjar01]

Instead of watching a 2-hour movie, watch this masterclass on wealth creation

Book mark it!!

[James Clear @JamesClear]

Clarity isn't about knowing what you want to do with your life, it's about knowing what you want to do this week. You don't need to have it all figured out. You just need to know your next step.

[MindIgnited @MindIgnite34371]

I’m 36, PEACE looks this to me now:

[James Clear @JamesClear]

A Monday morning question for you:

I recently asked a friend if he wanted to hit a certain business milestone and he said, "That depends. What does it cost me?"

Writing down your goals is easy. Everybody wants the glamorous result. What really matters is whether you want the costs associated with it: the money, the time, the tradeoffs.

Don't merely ask yourself what do I want to achieve, but also what am I willing to pay?

[Advait Arora @WealthEnrich]

🇮🇳💊 India’s CDMO Story Has Finally Reached the P&L

5 CDMO-linked companies have reported revenue growth of 19% to 67%. In two cases, EBITDA grew more than 70%.

The Long-Standing Thesis: Global pharmaceutical companies want to reduce dependence on China. India offers a massive pool of process chemists, hundreds of US FDA-regulated manufacturing plants, and a 30% to 40% cost advantage over Western manufacturers.

The Reality Check: Investors are not rewarded merely because a pitch deck mentions "China+1." The real test is whether years of R&D and thousands of crores in capex actually turn into revenue, margins, and cash flow.

The Turnaround: Latest quarterly numbers confirm that this conversion from investments to actual profits has officially begun.

📈 Recent Quarterly Breakthroughs
Laurus Labs: CDMO revenue jumped 67% to ₹870 crore (up from ₹522 crore).
OneSource Specialty Pharma: Revenue grew 37% to ₹449 crore; EBITDA increased 39% with EBITDA margins reaching 27.5%.
Acutaas Chemicals (formerly Ami Organics): Revenue surged 59% to ₹330 crore; EBITDA soared 122% to ₹113 crore (margins crossed 34%).
Piramal Pharma: CDMO revenue grew 19% to ₹1,187 crore; consolidated EBITDA rose 72% (margins expanded from 8.5% to 12.5%).
Senores Pharmaceuticals: Revenue expanded 36% to ₹180 crore; EBITDA grew 87% to ₹54 crore. Its regulated-market business grew 42% with 16 commercial CDMO/CMO products supplying the US market.

WAHT THIS INDICATES: Newly built capacity is finding active customers, more projects are entering commercial production, and profits are compounding faster than sales.

🌐 How Large Can the Indian CDMO Opportunity Become?

Broader Market Estimate: The Indian pharmaceutical contract manufacturing market is projected to grow from $25.81 billion in 2025 to $51.18 billion by 2030 (CAGR of 14.67%).

Narrower Estimate (Kearney): Focuses specifically on high-value CDMO services, estimating the market to reach $18 billion–$19 billion by 2030 (CAGR of 14%–15%).

Key Takeaway for Investors: Regardless of definitions, both estimates confirm sustained, double-digit growth for the rest of this decade.

🔄 Why CDMO Changes Company Economics

Old Indian Pharma Model: Focused on generic drugs and bulk APIs. Patents expired, Indian players made cheaper copies, and companies fought purely on price and scale.

New CDMO Partnership Model: Work begins while a drug is still in clinical trials. The Indian partner helps design manufacturing processes, improve yield, build clinical batches, and clear regulatory hurdles.

High Switching Costs: Once a drug is approved for commercial scale, switching the CDMO partner requires tech transfers, new validation batches, stability studies, and fresh regulatory approvals—making trusted partners almost impossible to replace.

Pipeline Quality over Quantity: Having 100 early-stage projects matters less than having 3 or 4 late-stage/commercial blockbusters that generate massive, steady cash flows.

🧬 Moving Into More Complex Chemistry

Moving Up the Value Chain: Indian CDMOs are pivoting away from simple APIs into peptides, GLP-1 drugs, antibody-drug conjugates (ADCs), biologics, complex injectables, sterile fill-and-finish, oligonucleotides, and cell/gene therapies.

Laurus Labs: Has 125+ active CDMO projects and is building platforms in peptides, fermentation, gene therapy, and ADCs.

OneSource Specialty Pharma: Focuses on biologics, sterile injectables, drug-device combos, and GLP-1 products (boosted by commercial launches of semaglutide in India and Canada).

Acutaas Chemicals: Expanding advanced chemistry expertise beyond pharma into specialty areas like semiconductor and battery chemicals.

Cohance Lifesciences (Suven Platform): Expanding into niche areas like oligonucleotides and antibody-drug conjugates (ADCs).

📊 22 Indian CDMO & Outsourcing Stocks Worth Studying
1. Research-Led & Integrated CRDMO Platforms
💊 Sai Life Sciences
💊 Syngene International
💊 Anthem Biosciences
💊 Laurus Labs
💊 Cohance Lifesciences
💊 Piramal Pharma
💊 OneSource Specialty Pharma
(These span early discovery, process engineering, clinical supply, and commercial scale).

2. Complex Chemistry, APIs & Intermediates
💊 Divi’s Laboratories
💊 Neuland Laboratories
💊 Blue Jet Healthcare
💊 Acutaas Chemicals
💊 Aether Industries
💊 Aarti Pharmalabs
💊 Hikal
💊 Alivus Life Sciences
💊 Supriya Lifescience
(Ranges from niche custom synthesis to API leaders capturing higher-value CDMO work).

3. Formulations & Contract Manufacturing (CMO)
💊 Akums Drugs
💊 Windlas Biotech
💊 Senores Pharmaceuticals
💊 Gland Pharma
💊 Jubilant Pharmova
💊 Dr. Reddy’s Laboratories
(Focuses on finished formulations, injectables, and generic contract manufacturing—should not automatically be valued like pure-play discovery CRDMOs).

🎯 What to Watch as an Investor

Project Quality over Count: Prioritize how many molecules reach Phase 3 or commercial production over vanity metrics of early-stage trial.
Capex Conversion: Track customer plant audits, asset turnover, capacity utilization, and incremental return on capital (ROCE).
Customer Concentration: Watch out for over-dependence on a single client or single "blockbuster" drug.
Margin Sustainability: Separate genuine long-term operating leverage from temporary margin bumps driven by one-off orders.
Valuation Discipline: A great business growing at 25% can still yield poor stock returns if the price already discounts 35% growth for the next five years.

💡 The Bottom Line
The Big Shift: India is moving from being the "Pharmacy of the World" (cheap generics) to an indispensable co-developer of global life-saving drugs.
The Winners: Not all 22 companies will succeed & yes some will face unutilized capacity or customer concentration risks.

--> The Sweet Spot: Identify companies so deeply embedded in their client's drug journey that replacing them would be too slow, risky, and expensive for global pharma giants.

[Amit @aiamit1]

Happy Friendship Day everyone 🤝❣️
#HappyFriendshipDay

[Chart Wallah @Chart_Wallah108]

𝗧𝗼𝗽 1𝟬 𝗕𝗹𝗼𝗰𝗸𝗯𝘂𝘀𝘁𝗲𝗿 𝗤𝟭 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 💥

Highly Undervalued Smallcaps 🔥🔥

A Mega ( Thread )🧵

Save it for Later 🔖

10 Multibaggers below 👇🏻